We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-7.92%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$670M
AUM Growth
-$18.2M
Cap. Flow
-$335M
Cap. Flow %
-50.06%
Top 10 Hldgs %
86.43%
Holding
215
New
27
Increased
46
Reduced
57
Closed
68

Top Buys

Rank Stock Value
1
NRXP icon
NRX Pharmaceuticals
NRXP
+$2.55M
2
TANH icon
Tantech Holdings
TANH
+$2.26M
3
AGTC
Applied Genetic Technologies Corporation
AGTC
+$1.76M
4
ZVRA icon
Zevra Therapeutics
ZVRA
+$1.52M
5
NBEV
NewAge, Inc. Common Stock (Delaware)
NBEV
+$1.12M

Top Sells

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$17.7M
2
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$10.2M
3
ROI
RiskOn International, Inc. Common Stock
ROI
+$7.16M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.75M
5
SLAI
SOLAI Ltd ADS
SLAI
+$5.55M

Sector Composition

Rank Sector Weight
1 Healthcare 7.59%
2 Technology 1.45%
3 Financials 0.54%
4 Consumer Discretionary 0.53%
5 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TKAT
201
DELISTED
Takung Art Co., Ltd.
TKAT
– –
-576,729
Closed -$2.34M
INFI
202
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-4,321
Closed -$972K
OIG
203
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
– –
-4,626
Closed -$405K
SRNE
204
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-2,189,700
Closed -$10.2M
SRNE
205
PUT
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-21,897
Closed -$13.2M
NBEV
206
CALL
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
– –
-11,132
Closed -$1.15M
ATHX
207
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-161
Closed -$364K
GPL
208
DELISTED
Great Panther Mining Limited
GPL
– –
-1,150,449
Closed -$2.52M
SRGA
209
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-15,633
Closed -$238K
NBRV
210
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-2,682
Closed -$40K
NBRV
211
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-27
Closed -$40K
5 6 7 8
9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2022 Portfolio in Review

As of Q1 2022, Sabby Management held 215 positions worth $670M, down 2.6% from $688M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Sabby Management withdrew a net $335M in Q1 2022, closing 68 positions and reducing 57 holdings. Its most notable exit was Bit Digital, an estimated $17.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.6% of assets, up from 7.4% a quarter earlier, followed by Technology and Financials.

Against the trend, Sabby Management opened a new position in NRX Pharmaceuticals worth $1.92M.

  • Sabby Management's largest Q1 2022 buy was NRX Pharmaceuticals: 78,247 shares worth $1.92M.
  • Sabby Management added most to Tantech Holdings in Q1 2022, an estimated $2.26M increase.
  • Sabby Management's biggest Q1 2022 reduction was SOLAI Ltd ADS, cutting an estimated $5.55M.
  • Sabby Management fully exited Bit Digital in Q1 2022, selling an estimated $17.7M.
  • Sabby Management's ten largest holdings make up 86% of its $670M portfolio in Q1 2022.
  • Sabby Management opened 27 new positions and closed 68 in Q1 2022.
  • Sabby Management's portfolio value fell 2.6% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.